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Lung cancer is the leading cause of morbidity and death all over the world and asignificant burden on healthcare resources of most countries.1 Among the diverse
histologic subtypes, adenocarcinoma (AD) is the most common type of lung cancer in
both males and females in most countries, even in young people,2 and in tumors detected
in screening low-dose computed tomography programs.3,4 The characteristic mixture of
multiple subtypes has been a major source of inconsistency in subclassification in the past,
hence the axiom, the more tumor categories, the more difficulties in the diagnosis.
Therefore, new diagnostic criteria and uniform and consistent terminology are needed to
improve accuracy and permit correlations between pathology and multiple patient char-
acteristics including clinical features, tumor staging, molecular signatures, prognostic and
predictive markers, and imaging data. Morphology still remains an agreed-on gold
standard for AD, but a global rethinking of its histopathologic basis by exploiting an
integrated multidisciplinary approach could really improve our diagnostic, prognostic, and
predictive capabilities. The issue of accurate subtyping of poorly differentiated tumors and
limited diagnostic material for predictive purposes is strictly intermingled with this
scenario and often presents a difficult challenge,5 because most lung cancer patients are
discovered with locally advanced or metastatic disease, so cytology or biopsy samples are
the only available material. Therefore, in the past, the term “non-small cell lung cancer,
not otherwise specified” has been encouraged6 mainly due to the lack of a clinical reason
to classify more precisely. This situation has led to the uncomfortable feeling that
histopathology is a finite and imperfect source of diagnostic, prognostic, or predictive
information in lung cancers and that molecular studies are more important than histology
for prognosis and prediction. For these reasons, this new multidisciplinary classification of
AD that is presented in the Journal under the aegis of three outstanding scientific
communities devoted to lung cancer, namely the International Association for the Study
of Lung Cancer, the American Thoracic Society, and the European Respiratory Society,
represents an extraordinary, meritorious, and almost herculean effort by Dr. William D.
Travis,7 which surely will contribute to address many contemporary issues and questions
on the subject of pulmonary AD through a close integration of pathologic, clinical,
molecular, and radiologic data.
There are several innovative aspects of this classification. First, it relies on a
multidisciplinary approach with integration of clinical, radiologic, molecular, and imaging
features. Second, there is a completely new proposal to provide diagnostic criteria and
terminology in small biopsies and cytology, a problem not addressed in previous World
Health Organization classifications. Third, for patients with advanced lung AD, epidermal
growth factor receptor mutation assessment is recommended, so small biopsy and
cytology specimens need to be processed strategically not only for diagnosis but also to
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preserve tissue for molecular testing. Fourth, for resected
ADs, the concepts of AD “in situ” (AIS) and minimally
invasive AD (MIA) are introduced to define a subset of
patients who should have a 100% disease-free survival. Fifth,
in patients with invasive ADs, the introduction of compre-
hensive histologic subtyping and classification according to
the predominant subtype has implications for prognosis and
clinical prediction that could help to identify patients for
adjuvant therapy even in early stage lung AD.8,9 Furthermore,
it improves stratification of invasive ADs to allow for mo-
lecular and radiologic correlations and ultimately may impact
on tumor, node, metastasis (TNM) staging if tumor size may
be better predicted by the invasive component size rather than
the gross diameter. The dogma that AD classification had to
rely exclusively on standard hematoxylin and eosin-stained
sections rather than under the guidance of findings stemming
from immunohistochemistry or molecular assays10 has been
overcome in the present classification, particularly in small
biopsies.11
Although this classification of AD still uses a rather
traditional language, there are significant improvements in
comparison with the previous schemes.10,12 First, a clear
subdivision of AD-related lesions into preinvasive and inva-
sive growths, the former comprising atypical adenomatous
hyperplasia and the new concept of AIS (nonmucinous and
mucinous types) to replace the time-honored and often mis-
interpreted term of bronchioloalveolar carcinoma (BAC), and
the latter made of actually invasive tumors classified
according to predominant growth patterns and variants.
The sharing of a continuum of morphological changes
between adenomatous hyperplasia and nonmucinous AIS,
a cytologically low-grade lesion composed of Clara cells
and/or type II pneumocytes growing along preexisting
alveolar/bronchiolar structures (lepidic pattern) but lacking
pleural, stromal, or vascular invasion, makes an unifying
concept of preinvasive neoplastic lesions possible with asso-
ciated risk of progression to invasive tumors.13 The nosologic
position of mucinous AIS still remains debated, and this term
should be limited to rare, small-sized, circumscribed, and
solitary lesions featuring bland mucinous cells sometimes
resembling bronchial goblet cells. The assumption that AIS is
a cytologically bland lesion devoid of any invasion but
capable of further molecular changes and progression to
eventual invasive AD helps us to distinguish this event from
lepidic growths of invasive primary or even metastatic AD,
which usually are of higher grade. The strict definition of
AIS, however, should avoid continuing the improper use of
the term BAC abused until recently to indicate both nonin-
vasive and invasive AD with different histologic features and
clinical behavior. The upper limit of 3 cm for AIS should
allow for complete histologic sampling and avoiding confu-
sion with larger tumors for which there is insufficient evi-
dence that they will have a 100% disease-free survival. When
the next TNM revision is developed, AIS should belong to
“pTis” category in keeping with the general rules of TNM
system. Five-year disease-free survival of AIS is 100% pa-
tients because of the absence of any invasive component.
Another innovation of the present classification is the
introduction of the category of MIA for indicating a usually
nonmucinous, lepidic predominant, and low-grade tumor,
measuring 3 cm or less, with invasion being limited up to a
maximum 5 mm (either showing subtypes other than a lepidic
pattern or myofibroblastic stroma). The lack of vascular or
pleural invasion or tumor necrosis justifies the excellent prog-
nosis of this tumor type close to 100% just like AIS. In the next
TNM revision, MIA may be classified as “pTmi.” In invasive
AD where the invasion focus is 5 mm, the approach of this
new classification raises the consideration that the size of the
invasive components on histologic slides or the solid component
on computed tomography scan may be appropriate for sizing T
factor, if validated by additional studies.
Among invasive AD, quite wise has been the replace-
ment of the confusing mixed subtype AD, by the new ap-
proach of classification according to the predominant growth
patterns and variants by semiquantitative assessments in 5 to
10% increments to reflect the spectrum of diverse histologic
subtypes in these tumors and different molecular properties.
This approach could ameliorate the diagnostic reproducibility
of AD and allow for data sharing and comparability. Among
growth patterns, a new category of invasive AD with pre-
dominant nonmucinous lepidic component resembling AIS/
MIA has been devised to replace the confusing term AD with
BAC features. Other new entries include AD with a predom-
inant micropapillary pattern (similar to analogous life-threat-
ening tumors arising in breast, urinary bladder, or ovary),
invasive mucinous AD (formerly known as mucinous BAC),
and enteric AD with intestinal differentiation. Signet ring cell
and clear cell AD disappear as individual entities because
they are regarded as cytological changes occurring in multi-
ple histologic patterns, but when these features are identified
even in small amounts, they should be recorded in the
diagnosis preferably quantifying them, so the presence of
these cytologic features will be reported more often than in
prior classifications. This AD classification according to the
predominant histologic subtypes has prognostic,7,14–17 molec-
ular,7,18 and predictive7 implications; may also assist to dis-
tinguish multiple lung primaries from metastases19; and is
robustly correlated with either radiologic imaging counter-
parts14 or TNM staging according to the proportion of AIS
component and may support an architectural approach to
grading based on the growth patterns.20
Commendable is the recommendation to assess any
advanced lung AD for epidermal growth factor receptor
mutations and the encouragement to be aware of the impor-
tance of molecular studies. This is a rapidly evolving field,
and hopefully, in the near future, additional molecular bi-
omarkers will be validated in clinical trials testing new target
therapies (e.g., crizotinib for anaplastic lymphoma kinase
translocation). So, managing appropriately small biopsy and
cytology specimens should thus become a strategic goal not
only for rendering final diagnoses but also to preserve tissue
for further molecular testing. A true paradigm shift of the
traditional morphology-based approach and an authentic rev-
olution of this classification regards the recommendation of
relying on ancillary tools (immunohistochemistry and multi-
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disciplinary setting) when rendering different diagnoses in
small cytology and biopsy specimens,10 to limit the category
of non-small cell lung cancer—not otherwise specified to
only those cases in which morphology, immunohistochemis-
try, and multidisciplinary setting are not contributory.
Summing up, I feel that the present classification by Dr.
Travis is a valuable global rethinking of lung AD, which finds
its strength and innovation in a close integration of improved
morphology, clinical and imaging data, immunohistochemistry
use, and molecular assays. Thus, this classification is likely to
become a common language and denominator among patholo-
gists worldwide, especially those who are engaged with the
patient care by moving beyond diagnostics.21
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